HCWB (HCW Biologics) Accounts Payable: $11.79 Mil (As of Mar. 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $4.74
GF Value $43.79
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Accounts Payable?

HCW Biologics HCWB -8.22% 39 Accounts Payable is $11.79 Mil as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $43.79 (Possible Value Trap). The stock has 7 warning signs investors should review.

HCW Biologics's Accounts Payable for the quarter that ended in Mar. 2026 was $11.79 Mil.

HCW Biologics's quarterly Accounts Payable declined from Sep. 2025 ($18.97 Mil) to Dec. 2025 ($13.14 Mil) and declined from Dec. 2025 ($13.14 Mil) to Mar. 2026 ($11.79 Mil).

HCW Biologics's annual Accounts Payable increased from Dec. 2023 ($6.17 Mil) to Dec. 2024 ($22.33 Mil) but then declined from Dec. 2024 ($22.33 Mil) to Dec. 2025 ($13.14 Mil).

HCW Biologics Accounts Payable Related Terms

HCW Biologics Accounts Payable Historical Data

* Premium members only.

The historical data trend for HCW Biologics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCW Biologics Accounts Payable Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 0.22 1.23 6.17 22.33 13.14

HCW Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.73 19.35 18.97 13.14 11.79
HCWB
39GF Score
HCW Biologics Inc HCWB
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $11.79 Mil mean?
HCW Biologics (HCWB) has a Accounts Payable of $11.79 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on HCW Biologics and its competitors.
Is HCW Biologics' Accounts Payable too high?
HCW Biologics' current Accounts Payable is $11.79 Mil. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Accounts Payable compare to KAPA and IMNN?
HCW Biologics' Accounts Payable of $11.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on HCW Biologics and its competitors. HCW Biologics's current Accounts Payable is $11.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.79, compared to a current price of $4.74 — trading 89.2% below its estimated fair value. The current Accounts Payable is $11.79 Mil. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Accounts Payable is $11.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $4.74 is trading 89.2% below its estimated GF Value™ of $43.79. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Accounts Payable: $11.79 Mil
  • GF Value™: $43.79 vs. price of $4.74 (89.2% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.74
Price
$43.79
GF Value